High-conviction. Mechanism-rich. Genetically grounded.
AlphaMeld is modality-agnostic by design. Small molecules, biologics, peptides, ADCs, and gene therapies all reason over the same biological substrate, so the right therapeutic format for each program emerges from the data — not the toolkit.
Obesity & Metabolic
Oral, non-incretin programs designed to complement GLP-1 / GIP standards of care. Genetic-led discovery; modality-agnostic across small molecule, biologic, and peptide formats.
Inflammation & Immunology
Selective oral kinase inhibitors and innate-immune modulators. Psoriasis, IBD, atopic dermatitis, lupus.
GBA & Lysosomal
Genetic Parkinson's and Gaucher-spectrum lysosomal disorders. Chaperones, substrate reduction, gene therapy adjacents.
Oncology — Solid Tumors
Synthetic-lethal targets, MSI-H biomarker-led indications, ADC payload class evaluation.
Neurodegeneration
Microglia modulators, tau, ApoE-stratified Alzheimer's. Biomarker-driven trial design.
Rare Disease
Orphan-stratified target ID. Genetic validation as primary signal. Partnered & wholly-owned.
Cardio-Renal
Lipid-genetics-led cardio programs and CKD with metabolic comorbidity.
Women's Health
Mechanism-rich, historically under-resourced indications. RWE-grounded prioritization.